首页|腹膜透析与高通量血液透析治疗终末期肾病患者的效果比较

腹膜透析与高通量血液透析治疗终末期肾病患者的效果比较

扫码查看
目的:比较腹膜透析与高通量血液透析治疗终末期肾病患者的效果.方法:回顾性分析 2021 年 1 月至 2023 年 6 月该院收治的 70 例终末期肾病患者的临床资料,按治疗方式不同将其分为对照组与观察组各 35 例.对照组采用高通量血液透析治疗,观察组采用腹膜透析治疗.比较两组治疗前后肾功能指标[血尿素氮(BUN)、血肌酐(Scr)、肾小球滤过率(GFR)、β2-微球蛋白(β2-MG)]水平、炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)]水平、T细胞亚群指标(CD4+、CD3+、CD8+、CD4+/CD8+)水平和并发症发生率.结果:治疗后,两组BUN、Scr、β2-MG水平均低于治疗前,且观察组低于对照组,两组GFR水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组TNF-α、IL-6、hs-CRP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组CD4+、CD3+、CD4+/CD8+水平均高于治疗前,且观察组高于对照组,两组CD8+水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组并发症发生率比较,差异无统计学意义(P>0.05).结论:腹膜透析治疗终末期肾病患者可改善肾功能指标和T细胞亚群指标水平,降低炎性因子水平,其效果优于高通量血液透析治疗.
Comparison of effects of peritoneal dialysis and high-flux hemodialysis in treatment of patients with end-stage renal disease
Objective:To compare effects of peritoneal dialysis and high-flux hemodialysis in treatment of patients with end-stage renal disease.Methods:The clinical data of 70 patients with end-stage renal disease admitted to this hospital from January 2021 to June 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,35 cases in each group.The control group was treated with high-flux hemodialysis,while the observation group was treated with peritoneal dialysis.The levels of renal function indexes[blood urea nitrogen(BUN),serum creatinine(Scr),glomerular filtration rate(GFR),β2-microglobulin(β2-MG)],inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),hyper-sensitive C-reactive protein(hs-CRP)]and T cell subsets(CD4+,CD3+,CD8+,CD4+/CD8+)before and after the treatment,and the incidence of complications were compared between the two groups before and after the treatment.Results:After the treatment,the levels of BUN,Scr and β2-MG in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the GFR levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of TNF-α,IL-6 and hs-CRP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD4+,CD3+and CD4+/CD8+in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the levels of CD8+in the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusions:Peritoneal dialysis in the treatment of the patients with end-stage renal disease can improve the levels of renal function indexes and T cell subsets,and reduce the levels of inflammatory factors.Moreover,it is superior to high-flux hemodialysis treatment.

High-flux hemodialysisPeritoneal dialysisEnd-stage renal diseaseRenal functionInflammatory factorT cell subset

焦林娟、陈庆云、王莹、周杨、刘萍

展开 >

南阳市第二人民医院肾病科,河南 南阳 473000

高通量血液透析 腹膜透析 终末期肾病 肾功能 炎性因子 T细胞亚群

2024

中国民康医学
中国社会工作协会

中国民康医学

影响因子:0.649
ISSN:1672-0369
年,卷(期):2024.36(16)